Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer

Cancer

Volumn 117, Issue 13, 2011, Pages 3004-3013

  Sejpal, Samir ^a   Komaki, Ritsuko ^a   Tsao, Anne ^a   Chang, Joe Y ^a   Liao, Zhongxing ^a   Wei, Xiong ^a   Allen, Pamela K ^a   Lu, Charles ^a   Gillin, Michael ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

esophagitis; lung cancer; pneumonitis; protein therapy; toxicity

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG DOSE REDUCTION; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ODYNOPHAGIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION PNEUMONIA; THROMBOCYTOPENIA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PNEUMONIA; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 79959627247     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25848     Document Type: Article

References (26)

1. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17: 2692-2699. (Pubitemid 29415225)
2. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment related pneumonitis (TRP) in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68: 94-102. (Pubitemid 46589835)
3. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1087-1096.
4. Greene FL, Page DL, Fleming ID, et al, eds. American Joint Committee on Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
5. Karnofsky DA, Burchenal JH., The clinical evaluation of chemotherapeutic agents in cancer. In:, Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949: 191-205.
6. Liu HH, Balter P, Tutt T, et al. Assessing respiration-induced tumor motion and internal target volume using 4-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 531-540. (Pubitemid 46694175)
7. Liao ZX, Komaki R, Thames HD Jr, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010; 76: 775-781.
8. Wang S, Liao Z, Liu HH, et al. Initial evaluation of clinical and dosimetric parameters associated with treatment-related pneumonitis in patients with non-small-cell lung cancer treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66: 1399-1407.
9. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys. 1991; 20: 1183-1190.
10. Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol. 2010; 28: 2475-2480.
11. Schild SE, McGinnis WL, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1106-1111.
12. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008; 26: 2457-2463.
13. Fang LC, Komaki R, Allen PK, et al. Comparison of outcomes for patients with medically inoperable stage I non-small-cell cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66: 108-116. (Pubitemid 44175656)
14. Zinner RG, Komaki R, Cox JD, et al. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 73: 119-127.
15. Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003; 57: 402-408. (Pubitemid 37040936)
16. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004; 58: 1369-1377. (Pubitemid 38438296)
17. Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2003; 21: 1767-1774. (Pubitemid 46638590)
18. Senzer N., A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification. Preliminary findings. Semin Oncol. 2002; 29: 38-41. (Pubitemid 36173245)
19. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol. 2005; 23: 2145-2154. (Pubitemid 46218706)
20. Wei X, Liu H, Tucker SL, et al. Risk factors for acute esophagitis in non-small cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66: 100-107. (Pubitemid 44175670)
21. Curran WJ Jr, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC. RTOG 9410 [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 621.
22. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume analysis for pneumonitis after 3D treatment for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999; 45: 323-329. (Pubitemid 29408545)
23. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001; 51: 650-659.
24. Willner J, Jost A, Baier K, et al. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol. 2003; 179: 548-556. (Pubitemid 36966412)
25. Tsujino K, Mirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 110-115. (Pubitemid 36020349)
26. Chang JY, Komaki R, Bucci MK, et al. Failure pattern and toxicity of concurrent proton therapy and chemotherapy for stage III non-small cell lung cancer [abstract 2590]. Int J Radiat Oncol Biol Phys. 2009; 75 (3 suppl): S446.